HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
VRDN
Viridian Therapeutics Inc
Healthcare Biotechnology · Colorado, USA · Reports in usd
Market Cap: $2.28B
Market Cap
$2.28B
Enterprise Val
$1.65B
P/E Ratio
-5.88
P/B Ratio
3.44
Trailing PEG (1Y)
-1.18
As Of
Aug 13, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$662.1M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-61.35%
Return on Assets-46.03%
Current Ratio16.95
Debt/Equity0.54
LT Debt/Equity0.54
Revenue Per Share0.00

Income Statement

Jun 30, 2026
Revenue$284.0K
Cost of Revenue$0.00
Gross Profit$284.0K
R&D$71.6M
SG&A$55.0M
Operating Expenses$126.6M
Operating Income-$126.3M
Interest Expense$8.3M
Tax Expense$0.00
Net Income-$127.1M
EPS (Basic)$-1.05
EPS (Diluted)$-1.05
EBIT-$118.8M
EBITDA-$118.7M
Consolidated Income-$127.1M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$165.0M
Accounts Receivable$75.0M
Inventory$0.00
Current Assets$1.08B
LT Investments$0.00
Property, Plant & Equipment$4.9M
Intangibles$10.0M
Non-Current Assets$16.0M
Total Assets$1.10B
Accounts Payable$8.7M
Current Debt$0.00
Current Liabilities$63.8M
LT Debt$355.8M
Non-Current Liabilities$371.3M
Total Liabilities$435.1M
Total Debt$355.8M
Retained Earnings-$1.57B
Shareholder Equity$662.1M
Shares Outstanding103,074,740

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$105.3M
Investing Cash Flow-$231.2M
Financing Cash Flow$325.1M
CapEx-$1.3M
Free Cash Flow-$106.6M
Depreciation & Amort.$89.0K
Stock-Based Comp$17.0M
Acquisitions / Disposals$0.00
Investment Activity-$229.9M
Debt Issued/Repaid$187.8M
Equity Issued/Repaid$137.3M
Dividends Paid$0.00
Net Change in Cash-$11.4M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h